Bliss GVS Pharma CEO steps down; new CEO and director appointed

Ceo ResignedCeo Appointed ExternalKmp ResignedManagement Changes View source PDF Explain this filing

BLISSGVS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.8%Reaction day

₹504.00

prior close

₹505.95

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.2%-3.0% vs market

Pharmaceuticals peers, median of 164sector-0.5%-2.3% vs sector

On the reaction day the stock moved 3.0 pts less than Nifty Microcap 250 and 2.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.7

10m

+1.4

15m

+0.7

30m

+0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.8+0.2-3.0-0.5-2.3

Next day

+0.6-0.5+1.1-0.7+1.3

+0.9-2.5+3.4-1.7+2.6

+4.5-0.6+5.2-1.3+5.9

+4.2+0.7+3.4-0.5+4.6

+5.2+0.9+4.3+0.2+4.9

+2.2+0.5+1.7+0.4+1.7

15d

-9.4-0.2-9.2-1.4-8.0

-2.4+2.9-5.3-1.4-1.0

+37.5+5.0+32.5+1.2+36.3

+35.5+3.7+31.8+0.4+35.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Bliss GVS Pharma announced a CEO transition. Mr. Narsimha Shibroor Kamath steps down as CEO effective July 14, 2026, but continues as Managing Director. Mr. Rahul Adakmol, an IIM Bangalore alumnus with 22 plus years of experience at Bharat Serums, Dr. Reddy's and Reliance, takes over as CEO from July 15. Also, Mr. Santosh Parab, a Chartered Accountant with 35 plus years of experience, joins as Additional Non-Executive Non-Independent Director.

Likely market impact

Leadership continuity maintained as outgoing CEO stays as MD; new CEO brings strong external pharma experience. Likely seen as a smooth, positive transition.